Metronomic Capecitabine Plus Aromatase Inhibitor for First Line Treatment in HR(+), Her2(-) Metastatic Breast Cancer
Clinical trial NCT02767661 · COMPLETED
Trial details
- NCT number
- NCT02767661
- Sponsor
- Sun Yat-sen University
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2017-07-19
- Primary completion
- 2023-08-25
- Enrollment
- 263
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.